lobbying_activities: 1191167

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1191167	deacd640-8797-4c16-a00e-a2f612f7bead	Q4	SHIRE PHARMACEUTICALS LLC	323477	SHIRE PHARMACEUTICALS LLC	2011	fourth_quarter	PHA	S. 296, Preserving Access to Life Saving Medicines Act; H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act (ULTRA); Life Sciences Investment Act Issues relating to R&D funding for rare disease products, biosimilars and other products; end stage renal disease (ESRD) orphan drugs; reimbursements; drug shortages; DEA quotas; prescription drug user fees; exclusivity periods	HOUSE OF REPRESENTATIVES,SENATE		110000	0	0	2012-01-18T14:22:18-05:00